-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82

Benzinga·09/16/2026 17:24:47
Listen to the news
Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.